External link, please review our disclaimer.

Guidelines for Developing a Data and Safety Monitoring Plan: Appendix A

Detailed DSM Plan Checklist

Download this file (PDF, 12KB)

Was item included in the DSM plan? Included?
Yes No
Brief description of the protocol    
Primary and secondary outcome measures    
Inclusion/exclusion criteria    
Sample size    
List of participating enrolling clinics or data collection centers    
Projected timetable    
Target population distribution (e.g., women, minorities, etc)    
Data acquisition and transmission    
Data entry methods    
Data analysis plan    
Quality assurance plan    
Reporting mechanisms of AEs/SAEs to the IRB, FDA, and NIDA.    
Reporting mechanisms of IRB actions to NIDA    
Report of changes or amendments to the protocol    
Trial stopping rules    
Conflict of interest    
Potential risks and benefits for participants    
Collection and reporting of AEs and SAEs    
Management of SAEs or other study risks    
Plans for Interim Analysis of efficacy data    
Responsibility for data and safety monitoring    
Frequency of DSM reviews    
Content of DSM report    
DSM Board Plan (if applicable)    

Search for Funding

Featured Publication

Mentoring, A Guide for Drug Abuse Researchers publication cover

Mentoring: A Guide for Drug Abuse Researchers

Discusses the importance of quality mentorship in drug abuse research and offers suggestions for creating a successful mentor and mentee relationship.

The National Institute on Drug Abuse (NIDA) is part of the National Institutes of Health (NIH), a component of the U.S. Department of Health and Human Services. NIH...Turning Discovery Into Health

National Institute on Drug Abuse   |   6001 Executive Boulevard, Room 5213   |   Bethesda, MD 20892-9561

Questions for our staff? E-mail information@nida.nih.gov or call 301-443-1124 (240-221-4007 en español).

Mobile Site